Biocon Limited (NSE:BIOCON) delivered a resilient operational performance in Q4FY26, driven by strong traction in its biosimilars business, improving execution across key global markets, and a gradual transition toward margin expansion after completing a major investment cycle. The company highlighted FY26 as a strategic inflection point as it completed its integration initiatives and strengthened its balance sheet for long-term value creation.
The company’s stock reacted positively after the earnings announcement, with shares rising over 2% intraday to around ₹390. Investors responded favorably to improving biosimilars growth momentum, operating leverage expectations, and management’s outlook for profitability improvement in FY27.
Q4 FY26 Financial Performance
Biocon reported Q4FY26 revenue from operations of ₹4,517 crore, registering adjusted year-on-year growth of 10%, while total revenue stood at ₹4,569 crore. EBITDA came in at ₹1,073 crore, up 29% YoY on an adjusted basis, with EBITDA margin remaining healthy at 23%.
Profit before tax before exceptional items rose sharply to ₹328 crore compared to an adjusted ₹185 crore in the corresponding quarter last year. Net profit before exceptional items increased 64% YoY to ₹179 crore, while reported net profit stood at ₹126 crore.
The biosimilars business remained the biggest contributor during the quarter, with segment revenue rising 12% YoY to ₹2,756 crore. EBITDA for the segment increased 33% YoY to ₹720 crore, supported by stronger North American demand, stable European execution, and improving product uptake.
The generics segment posted adjusted revenue growth of 13% YoY to ₹847 crore, aided by gLiraglutide launches in Europe and multiple approvals across regulated markets. Meanwhile, CRDMO revenue rose 2% YoY to ₹1,037 crore as the business maintained stable execution and client momentum.
FY26 Financial Performance
For the full financial year FY26, Biocon reported revenue from operations of ₹16,927 crore, reflecting adjusted growth of 13% year-on-year. Total revenue stood at ₹17,270 crore, while EBITDA increased 25% YoY to ₹3,798 crore on an adjusted basis. EBITDA margin for the year remained at 22%.
Net profit before exceptional items came in at ₹436 crore, compared with an adjusted ₹103 crore in FY25, reflecting significant operational improvement. Reported net profit stood at ₹386 crore for FY26.
The biosimilars segment reported FY26 revenue of ₹10,431 crore, up 16% YoY, while generics revenue rose 17% to ₹3,168 crore on an adjusted basis. CRDMO revenue increased 3% to ₹3,739 crore during the year.
Strategy and Outlook
Biocon stated that FY26 marked the completion of its corporate reorganization and integration process, enabling the company to function as one unified global biopharma platform. The management indicated that the company is now transitioning from an investment-heavy phase toward execution, utilization improvement, and operating leverage expansion.
The company also emphasized meaningful progress in deleveraging and strengthening financial flexibility. Management expects recently commissioned biosimilars, peptides, insulins, and complex generics capacities to gradually contribute toward profitability enhancement.
Looking ahead to FY27, Biocon expects scaling of recent biosimilar launches, improved profitability in the generics segment, and more stable performance from Syngene operations. Margin expansion and return-on-capital improvement remain key strategic priorities for the company.
Technical Summary
Biocon shares traded near ₹390 after rebounding decisively above the 50-day SMA around ₹371. The stock has formed a bullish recovery structure with improving volumes and positive momentum. Immediate resistance is visible near ₹400–₹405, while strong support is placed around ₹370–₹375, keeping the near-term technical trend constructive.
Chart by TradingView
Conclusion
Biocon’s FY26 performance reflects improving operational strength following years of investment and integration. Strong biosimilars growth, expanding global approvals, and better operating leverage position the company for sustainable long-term growth. Margin recovery, scaling of recent launches, and continued balance-sheet improvement are expected to remain key investor focus areas during FY27.
FAQs
- What drove Biocon’s Q4FY26 growth?
Strong biosimilars demand, new product launches, and improving market penetration across North America and Europe supported quarterly growth significantly. - How did Biocon’s biosimilars segment perform in FY26?
The biosimilars business recorded 16% annual revenue growth with improving margins and strong traction across key regulated global markets. - What is Biocon’s outlook for FY27?
Biocon expects stronger operating leverage, margin improvement, higher biosimilar utilization, and improved profitability across major business segments.